In a nutshell This trial compared the use of standard paclitaxel (SP; Taxol) versus a new nanoparticle micellar preparation of paclitaxel (NmP) as a first-line treatment for non-small cell lung cancer (NSCLC). The authors found that NmP had better effectiveness and safety in treating NSCLC than SP. Some...
Read MoreType of lung cancer-Non-small cell lung carcinoma (NSCLC) Posts on Medivizor
Does immune checkpoint therapy and radiotherapy combination improve response in treating brain metastasis from non-small cell lung cancer and melanoma?
In a nutshell The study evaluated the timing of radiotherapy (RT) and immune-checkpoint therapy (ICT) on the outcomes of patients with brain metastasis (BrM) resulting from melanoma and non-small cell lung cancer (NSCLC). The authors found that RT and ICT given at the same time may improve response and delay recurrence in these patients. Some...
Read MoreDoes immune checkpoint therapy and radiotherapy combination improve response in treating brain metastasis from non-small cell lung cancer and melanoma?
In a nutshell The study evaluated the timing of radiotherapy (RT) and immune-checkpoint therapy (ICT) on the outcomes of patients with brain metastasis (BrM) resulting from melanoma and non-small cell lung cancer (NSCLC). The authors found that RT and ICT given at the same time may improve response and delay recurrence in these patients. Some background...
Read MoreCan erlotinib be used at a reduced dose to treat EGFR-mutated advanced non-small cell cancer?
In a nutshell This study was carried out to look at the use of a reduced dose of erlotinib (Tarceva) in the treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC). The authors found that lower-dose erlotinib was as effective as standard dose gefitinib (Iressa) in these patients. Some background NSCLC is the...
Read MoreDoes chemoimmunotherapy have additional survival benefits compared to immunotherapy alone in the treatment of advanced non-small cell lung cancer?
In a nutshell This study was carried out to compare the effectiveness of chemoimmunotherapy (CIT) to immunotherapy (IT) alone for advanced non-small cell lung cancer (NSCLC). The authors found that there was no significant benefit in overall survival with CIT over IT. Some background NSCLC is the most common form of lung cancer. NSCLC is responsible...
Read MoreSearching for patients with non-small cell lung cancer to trial an immune treatment
In a nutshell This trial is being carried out to examine the effectiveness of a new immune therapy, zimberelimab, alone or in combination with other immune therapies (domvanalimab and etrumadenant) in patients with PD-L1 positive non-small cell lung cancer (NSCLC). The main outcomes to be measured in this trial is the response rate and survival...
Read MoreEvaluating osimertinib for EGFR positive non-small-cell lung cancer that was surgically removed.
In a nutshell This trial was carried out to assess the effectiveness and safety of osimertinib (Tagrisso) after surgery for EGFR-positive advanced non-small cell lung cancer (NSCLC). The trial found that this treatment improved the outcomes of patients with stage IB to IIIA EGFR-positive NSCLC that was surgically removed. Some...
Read MoreIs gefitinib beneficial when combined with chemotherapy in the treatment of non-small cell lung cancer?
In a nutshell This article looked at the effectiveness of gefitinib (Iressa) combined with chemotherapy when compared to a chemotherapy aline in the treatment of non-small cell lung cancer (NSCLC). The authors found that the addition of gefitinib to a chemotherapy increased the progression-free survival (PFS) of these...
Read MoreSearching for patients with stage III non-small cell lung cancer to trial a biological treatment.
In a nutshell This trial is aiming to examine the effectiveness and safety of atezolizumab (Tecentriq) and tiragolumab compared to durvalumab (Imfinzi) in stage III non-small-cell lung cancer (NSCLC) that cannot be surgically removed and has previously been treated with concurrent (at the same time) platinum-based chemoradiation therapy (CRT)....
Read MoreComparing the effects of brigatinib versus crizotinib in patients with non-small cell lung carcinoma
In a nutshell The study evaluated outcomes of brigatinib (Alunbrig) versus crizotinib (Xalkori) in patients with non-small cell lung carcinoma (NSCLC) and anaplastic lymphoma kinase (ALK) mutations, who were previously not treated with ALK inhibitors (ALKI). The main finding was that brigatinib had better long-term outcomes compared to crizotinib in such...
Read MoreLooking for patients with metastatic lung cancer to trial a treatment combination
In a nutshell This trial is being carried out to assess whether osimertinib (Tagrisso) should be used alone or with chemotherapy for lung cancer and abnormalities (mutations) in the EGFR gene. The main outcome that will be measured in this trial is survival without progression of the disease. This trial will take place in New Jersey and New...
Read MoreLooking for patients with stage III non-small cell lung cancer to trial a treatment combination with radiotherapy
In a nutshell This study is looking to examine the effectiveness of durvalumab (Imfinzi) and consolidation stereotactic body radiation therapy (SBRT) after chemoradiation for locally advanced stage III non-small-cell lung cancer (NSCLC). The main outcomes to be measured are the occurrence of side effects and the survival without cancer...
Read More